FDA
-
-
-
-
-
-
-
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
-
-
-
-
-
-
-
Immunic Inc. (IMUX) Reports 200 Patients Enrolled in Phase 2 CALVID-1 Trial of IMU-838 for Treatment of Moderate COVID-1
-
-
-
-
-
-
-
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
-
-
-
-
-
-
-
Pre-Open Movers 07/11: (IMUX) (OMER) (DVAX) (CI) (CVS) (WW) (SNSS) (BBBY) (FAST) (more...)
-
322,098 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

